Cargando…

Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage

BACKGROUND: Most of the actions of thyroid hormone (TH) on body metabolisms like maintenance of basal metabolic rate (BMR) and body fat are similar to that of fibroblast growth factor 21 (FGF21). We hypothesized that in patients with hyperthyroidism, the pathological changes in the BMR, body fat are...

Descripción completa

Detalles Bibliográficos
Autores principales: Bande, Aashish Reddy, Kalra, Pramila, Dharmalingam, Mala, Selvan, Chitra, Suryanarayana, K M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873261/
https://www.ncbi.nlm.nih.gov/pubmed/31803597
http://dx.doi.org/10.4103/ijem.IJEM_273_19
_version_ 1783472631078453248
author Bande, Aashish Reddy
Kalra, Pramila
Dharmalingam, Mala
Selvan, Chitra
Suryanarayana, K M
author_facet Bande, Aashish Reddy
Kalra, Pramila
Dharmalingam, Mala
Selvan, Chitra
Suryanarayana, K M
author_sort Bande, Aashish Reddy
collection PubMed
description BACKGROUND: Most of the actions of thyroid hormone (TH) on body metabolisms like maintenance of basal metabolic rate (BMR) and body fat are similar to that of fibroblast growth factor 21 (FGF21). We hypothesized that in patients with hyperthyroidism, the pathological changes in the BMR, body fat are mediated by TH through FGF21. OBJECTIVES: To study the association of serum FGF21 levels with hyperthyroidism and correlate body fat percentage with serum FGF21 levels in hyperthyroid patients. STUDY DESIGN: Case-control prospective follow-up study. METHODOLOGY: A total of 68 hyperthyroid patients and age, sex-matched healthy controls who fulfilled the inclusion and exclusion criteria were studied. Among them, 45 cases were followed up at 3 to 6 months after the achievement of euthyroidism. Body fat percentage was calculated from Jackson and Pollock 3 site equation and Siri equation. BMR percentage was calculated by the Gale formula. RESULTS: The mean age in years in the cases was similar to that of controls (36.14 ± 10.01 vs. 36.57 ± 10.53, P = 0.81). The serum FGF21 levels at baseline were significantly elevated in patients with hyperthyroidism compared to controls [median 406.6 pg/ml (interquartile range, 262.9–655.6) vs. 252.3 (125.1–341) P < 0.001] and declined dramatically following treatment with anti-thyroid drugs [405 (275.5–680.4) vs. 203.6 (154.6–230.6) P < 0.001]. Serum FGF21 levels negatively correlated with body fat percentage (r = –0.268, P = 0.002). After adjusting to various confounding factors, serum FGF21 was independently associated with hyperthyroidism and was significant. (OR [95%CI] 3.78 (1.046–13.666) P = 0.043). CONCLUSION: Serum FGF21 levels were elevated in hyperthyroid patients and decreased following treatment with anti-thyroid drugs. It was independently associated with hyperthyroidism. There may be a future therapeutic role of FGF21 inhibition in the reversal of these changes in addition to anti-thyroid drugs in patients with hyperthyroidism.
format Online
Article
Text
id pubmed-6873261
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-68732612019-12-04 Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage Bande, Aashish Reddy Kalra, Pramila Dharmalingam, Mala Selvan, Chitra Suryanarayana, K M Indian J Endocrinol Metab Original Article BACKGROUND: Most of the actions of thyroid hormone (TH) on body metabolisms like maintenance of basal metabolic rate (BMR) and body fat are similar to that of fibroblast growth factor 21 (FGF21). We hypothesized that in patients with hyperthyroidism, the pathological changes in the BMR, body fat are mediated by TH through FGF21. OBJECTIVES: To study the association of serum FGF21 levels with hyperthyroidism and correlate body fat percentage with serum FGF21 levels in hyperthyroid patients. STUDY DESIGN: Case-control prospective follow-up study. METHODOLOGY: A total of 68 hyperthyroid patients and age, sex-matched healthy controls who fulfilled the inclusion and exclusion criteria were studied. Among them, 45 cases were followed up at 3 to 6 months after the achievement of euthyroidism. Body fat percentage was calculated from Jackson and Pollock 3 site equation and Siri equation. BMR percentage was calculated by the Gale formula. RESULTS: The mean age in years in the cases was similar to that of controls (36.14 ± 10.01 vs. 36.57 ± 10.53, P = 0.81). The serum FGF21 levels at baseline were significantly elevated in patients with hyperthyroidism compared to controls [median 406.6 pg/ml (interquartile range, 262.9–655.6) vs. 252.3 (125.1–341) P < 0.001] and declined dramatically following treatment with anti-thyroid drugs [405 (275.5–680.4) vs. 203.6 (154.6–230.6) P < 0.001]. Serum FGF21 levels negatively correlated with body fat percentage (r = –0.268, P = 0.002). After adjusting to various confounding factors, serum FGF21 was independently associated with hyperthyroidism and was significant. (OR [95%CI] 3.78 (1.046–13.666) P = 0.043). CONCLUSION: Serum FGF21 levels were elevated in hyperthyroid patients and decreased following treatment with anti-thyroid drugs. It was independently associated with hyperthyroidism. There may be a future therapeutic role of FGF21 inhibition in the reversal of these changes in addition to anti-thyroid drugs in patients with hyperthyroidism. Wolters Kluwer - Medknow 2019 /pmc/articles/PMC6873261/ /pubmed/31803597 http://dx.doi.org/10.4103/ijem.IJEM_273_19 Text en Copyright: © 2019 Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Bande, Aashish Reddy
Kalra, Pramila
Dharmalingam, Mala
Selvan, Chitra
Suryanarayana, K M
Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title_full Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title_fullStr Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title_full_unstemmed Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title_short Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage
title_sort serum fibroblast growth factor 21 levels in patients with hyperthyroidism and its association with body fat percentage
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873261/
https://www.ncbi.nlm.nih.gov/pubmed/31803597
http://dx.doi.org/10.4103/ijem.IJEM_273_19
work_keys_str_mv AT bandeaashishreddy serumfibroblastgrowthfactor21levelsinpatientswithhyperthyroidismanditsassociationwithbodyfatpercentage
AT kalrapramila serumfibroblastgrowthfactor21levelsinpatientswithhyperthyroidismanditsassociationwithbodyfatpercentage
AT dharmalingammala serumfibroblastgrowthfactor21levelsinpatientswithhyperthyroidismanditsassociationwithbodyfatpercentage
AT selvanchitra serumfibroblastgrowthfactor21levelsinpatientswithhyperthyroidismanditsassociationwithbodyfatpercentage
AT suryanarayanakm serumfibroblastgrowthfactor21levelsinpatientswithhyperthyroidismanditsassociationwithbodyfatpercentage